FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040711943> ?p ?o ?g. }

• W3040711943 endingPage "690" @default.
• W3040711943 startingPage "684" @default.
• W3040711943 abstract "ABSTRACT Targeted alpha therapy (TAT) is a promising tumor therapy that can specifically transport α particle to the vicinity of tumor cells while the normal cells are only slightly irradiated. Mesothelin is a highly promising molecular signature for many types of solid tumors including malignant mesothelioma, pancreatic cancer, ovarian cancer and lung adenocarcinoma etc., while the expression in normal human tissues are limited, thus making mesothelin a promising antigen for TAT. Previously we developed a theoretical model that could predict and optimize in vitro screening of potential TAT drugs. The aim of the study is construction and preclinical evaluation of 211At labeled anti-mesothelin antibodies as potential TAT drugs. Mesothelin expression of two tumor cell lines were confirmed by flow cytometry, and their radiosensitivities were also evaluated. We used two kinds of anti-mesothelin antibodies, ET210–6 and ET210–28, to construct TAT drugs. Then, radiochemical purity, stability in vitro, affinity of the conjugates and mesothelin expression level were assessed. The specific killing of mesothelin-positive cancer cells treated by 211At-ET210–28 and 211At-ET210–6 were studied via Cell Counting Kit-8 assay and colony formation assay. 211At-ET210–28 and 211At-ET210–6 revealed excellent affinity and stability in both phosphate buffer saline and fetal bovine serum environment. Radiolabeled antibody conjugates bound specifically to mesothelin-positive cells in vitro. Both 211At-ET210–28 and 211At-ET210–6 could specifically kill mesothelin-positive cells with negligible damages to mesothelin-negative cells. Our findings provide initial proof-of-concept for the potential use of 211At labeled ET210–28/ET210–6 anti-mesothelin antibody in specific killings of mesothelin-positive tumor cells." @default.
• W3040711943 created "2020-07-16" @default.
• W3040711943 creator A5004031758 @default.
• W3040711943 creator A5015085116 @default.
• W3040711943 creator A5019290469 @default.
• W3040711943 creator A5031801474 @default.
• W3040711943 creator A5042990327 @default.
• W3040711943 creator A5067371414 @default.
• W3040711943 creator A5084589573 @default.
• W3040711943 creator A5090668333 @default.
• W3040711943 date "2020-07-10" @default.
• W3040711943 modified "2023-10-18" @default.
• W3040711943 title "Construction and Preclinical Evaluation of 211At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs" @default.
• W3040711943 cites W138135214 @default.
• W3040711943 cites W1533229981 @default.
• W3040711943 cites W1963646933 @default.
• W3040711943 cites W1978653793 @default.
• W3040711943 cites W1979568379 @default.
• W3040711943 cites W1988876801 @default.
• W3040711943 cites W1995837838 @default.
• W3040711943 cites W2013669569 @default.
• W3040711943 cites W2015961605 @default.
• W3040711943 cites W2028450449 @default.
• W3040711943 cites W2033785962 @default.
• W3040711943 cites W2039829298 @default.
• W3040711943 cites W2040500107 @default.
• W3040711943 cites W2041607504 @default.
• W3040711943 cites W2067656235 @default.
• W3040711943 cites W2080232352 @default.
• W3040711943 cites W2080585386 @default.
• W3040711943 cites W2091630347 @default.
• W3040711943 cites W2134845021 @default.
• W3040711943 cites W2159581345 @default.
• W3040711943 cites W2163292580 @default.
• W3040711943 cites W2218133630 @default.
• W3040711943 cites W2346497885 @default.
• W3040711943 cites W2370634676 @default.
• W3040711943 cites W2531335004 @default.
• W3040711943 cites W2542331600 @default.
• W3040711943 cites W2603665089 @default.
• W3040711943 cites W2756067071 @default.
• W3040711943 cites W2790943428 @default.
• W3040711943 cites W2919646118 @default.
• W3040711943 cites W2944344108 @default.
• W3040711943 doi "https://doi.org/10.1093/jrr/rraa049" @default.
• W3040711943 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7482154" @default.
• W3040711943 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32648573" @default.
• W3040711943 hasPublicationYear "2020" @default.
• W3040711943 type Work @default.
• W3040711943 sameAs 3040711943 @default.
• W3040711943 citedByCount "5" @default.
• W3040711943 countsByYear W30407119432021 @default.
• W3040711943 countsByYear W30407119432022 @default.
• W3040711943 crossrefType "journal-article" @default.
• W3040711943 hasAuthorship W3040711943A5004031758 @default.
• W3040711943 hasAuthorship W3040711943A5015085116 @default.
• W3040711943 hasAuthorship W3040711943A5019290469 @default.
• W3040711943 hasAuthorship W3040711943A5031801474 @default.
• W3040711943 hasAuthorship W3040711943A5042990327 @default.
• W3040711943 hasAuthorship W3040711943A5067371414 @default.
• W3040711943 hasAuthorship W3040711943A5084589573 @default.
• W3040711943 hasAuthorship W3040711943A5090668333 @default.
• W3040711943 hasBestOaLocation W30407119431 @default.
• W3040711943 hasConcept C121608353 @default.
• W3040711943 hasConcept C126322002 @default.
• W3040711943 hasConcept C153911025 @default.
• W3040711943 hasConcept C159654299 @default.
• W3040711943 hasConcept C185592680 @default.
• W3040711943 hasConcept C202751555 @default.
• W3040711943 hasConcept C203014093 @default.
• W3040711943 hasConcept C2777045440 @default.
• W3040711943 hasConcept C2780210213 @default.
• W3040711943 hasConcept C502942594 @default.
• W3040711943 hasConcept C553184892 @default.
• W3040711943 hasConcept C55493867 @default.
• W3040711943 hasConcept C71924100 @default.
• W3040711943 hasConcept C86803240 @default.
• W3040711943 hasConceptScore W3040711943C121608353 @default.
• W3040711943 hasConceptScore W3040711943C126322002 @default.
• W3040711943 hasConceptScore W3040711943C153911025 @default.
• W3040711943 hasConceptScore W3040711943C159654299 @default.
• W3040711943 hasConceptScore W3040711943C185592680 @default.
• W3040711943 hasConceptScore W3040711943C202751555 @default.
• W3040711943 hasConceptScore W3040711943C203014093 @default.
• W3040711943 hasConceptScore W3040711943C2777045440 @default.
• W3040711943 hasConceptScore W3040711943C2780210213 @default.
• W3040711943 hasConceptScore W3040711943C502942594 @default.
• W3040711943 hasConceptScore W3040711943C553184892 @default.
• W3040711943 hasConceptScore W3040711943C55493867 @default.
• W3040711943 hasConceptScore W3040711943C71924100 @default.
• W3040711943 hasConceptScore W3040711943C86803240 @default.
• W3040711943 hasFunder F4320321001 @default.
• W3040711943 hasIssue "5" @default.
• W3040711943 hasLocation W30407119431 @default.
• W3040711943 hasLocation W30407119432 @default.
• W3040711943 hasOpenAccess W3040711943 @default.
• W3040711943 hasPrimaryLocation W30407119431 @default.
• W3040711943 hasRelatedWork W2015961605 @default.

• next